Abbisko Therapeutics Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Shanghai China

Primary Industry

Biotechnology

About

Based in Shanghai, China and founded in 2016, Abbisko Therapeutics Co., Ltd. operates as a biotechnology company that focuses on the research and development of immunotherapeutics used to treat patients with chronic diseases and cancer. The company was founded by Hongping Yu, Yao-Chang Xu, and Zhui Chen. In January 2021, Abbisko Therapeutics raised USD 123 million in series D funding. Abbisko Therapeutics develops and discovers innovative targeted and immuno-oncology therapies to cure/treat cancer patients. The company also researches therapies in Immuno-Oncology Small Molecule Inhibitors, Targeted therapies for Asian prevalent cancer, and Other Therapeutic Areas. Abbisko Therapeutics plans to use the capital raised through its series d fundraise to advance its clinical programs and expand its pre-clinical pipeline.

Current Investors

Lilly Asia Ventures, Sinopharm Capital, TF Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.abbisko.com

Company Stage

Series D

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.